Table 2.
The relationship between SIRI status and clinicopathological factors in the colorectal cancer patients.
| Variables | High-SIRI group (n = 63) | Low-SIRI group (n = 336) | p-value |
|---|---|---|---|
| Age, yrs; ≤ 66, > 66 | 181 (53.8%) / 155 (46.1%) | 42 (66.7%) / 21 (33.3%) | 0.0721 |
| Males/females | 41 (65.1%) / 22 (34.9%) | 196 (58.3%) / 140 (41.7%) | 0.3319 |
| BMI, ≤ 22/ > 22 | 156 (46.7%) / 178 (53.3%) | 28 (44.4%) / 35 (55.6%) | 0.784 |
| Tumor location, right side/left side | 22 (34.9%) /41 (65.1%) | 109 (32.4%) / 227 (67.6%) | 0.7702 |
| Histology, well or moderate/others | 52 (82.4%) /11 (17.5%) | 301 (89.6%) / 35 (10.4%) | 0.1304 |
| Depth of tumor invasion, T1–T2/T3–T4 | 9 (14.3%) / 54 (85.7%) | 125 (37.2%) / 211 (62.8%) | 0.0001 |
| Lymph node metastasis, − / + | 217 (64.6%) /119 (35.4%) | 41 (65.1%) / 22 (34.9%) | 1.0000 |
| Lymph invasion, − / + | 203 (60.6%) /132 (39.4%) | 25 (39.7%) / 38 (60.3%) | 0.0033 |
| Venous invasion, − / + | 110 (32.8%) /225 (67.2%) | 11 (17.5%) / 52 (82.5%) | 0.0165 |
| CEA level, high/normal | 25 (39.7%) / 38 (60.3%) | 98 (29.3%) / 237 (70.7%) | 0.1044 |
| CA19-9 level, high/normal | 48 (14.3%) / 287 (85.7%) | 12 (19.1%) / 51 (80.9%) | 0.3397 |
| Adjuvant chemotherapy, − / + | 251 (75.2%) /83 (24.8%) | 47 (74.6%) / 16 (25.40%) | 1.000 |
SIRI Systemic inflammation response index, High-SIRI group SIRI > 1700, Low SIRI group SIRI ≤ 1700, BMI Body mass index, CEA Carcinoembryonic antigen, CA19-9 Carbohydrate antigen 19-9.